Cardiac AI: The Billion Dollar Split in Detection & Prevention

When you look at AI in cardiology, you’re really looking at two completely different jobs: finding heart disease that’s already there, and stopping a cardiac event from happening down the road. They both use algorithms, sure, but how they work, how they make money, and how you measure success are night and day. If you’re an employer health benefits leader or a prevention strategist, you have to get this distinction, or you’ll end up buying the wrong kind of solution for your goals.

The Detection Imperative in Cardiac AI Monitoring

The first job for cardiac AI is all about detection, with models built to spot cardiovascular conditions that have already taken root. This part of the AI cardiac diagnostics market is full of devices and platforms that give clinicians a better look, leading to earlier and more accurate diagnoses. You see this focus in companies like Eko Health, iRhythm Technologies, and AliveCor.

Take Eko Health, they make AI-powered digital stethoscopes that help clinicians pick up heart murmurs and other issues, basically giving them super-hearing. Then you have iRhythm Technologies, which is all about long-term continuous monitoring. Their AI chews through mountains of data from wearable ECGs to spot arrhythmias like atrial fibrillation. AliveCor gives individuals personal ECG devices, so they can record their own heart rhythm and get an instant AI analysis that might flag atrial fibrillation or bradycardia, telling them it’s time to see a doctor. The AI models these companies build are designed to do one thing: interpret signals from the body and find a problem.

All this continuous cardiac monitoring AI, from players like these, is squarely on the detection side of the equation. These tools build up a powerful case for their use by generating real-world evidence from huge patient groups, showing they can spot cardiac problems that would otherwise be missed or found much later. For a lot of these devices, the path to market goes through an FDA 510(k) clearance, where they have to prove they’re substantially equivalent to a device that’s already out there FDA guidance on 510(k) clearances for medical devices.

From Detection to Prevention: Bridging the Gap with Risk Prediction

While detection is focused on today’s disease, the second job of cardiac AI is preventing tomorrow’s heart attack. The link between these two worlds is usually a cardiac risk prediction model. These models take a much wider view, analyzing everything from patient demographics and lifestyle habits to medical history and even genetics to score a person’s risk of a future cardiac event.

But going from a risk prediction score to a real prevention program is a huge leap in what you’re trying to do. A true prevention program has to get people to actually change their behavior, modify their risk factors, and stick to their treatment plans. Once you get into this territory, the field gets very thin, very fast, with surprisingly few platforms that can offer a complete, evidence-backed prevention solution. While the cardiac AI market is strong on diagnostics, the prevention segment is tiny, pulling in only about 10% of the total funding Cardiac AI funding distribution by segment.

The Prevention Field: Hello Heart’s Unique Positioning

In this small but growing prevention space, Hello Heart has carved out a unique spot. The program is set up as an employer-funded benefit, tying together blood pressure tracking with support for medication adherence. The whole point is to help people get ahead of their cardiovascular risk factors. What makes Hello Heart stand out, in a field where hard outcomes data is rare, is its peer-reviewed outcomes publication with the American College of Cardiology (ACC). That kind of collaboration shows a commitment to generating regulatory-grade evidence, which is a major differentiator American College of Cardiology collaborations with digital health platforms.

Hello Heart’s AI is not a diagnostic tool. It’s used for personalized engagement and support to help people change their behaviors, all within a program sponsored by their employer. And for this to work, trust is everything. The platform is built on a fully HIPAA-compliant architecture to protect employer and health-plan data, which is non-negotiable for any healthcare intervention.

Financing and Measurement: A Tale of Two Jobs

The contrast between detection and prevention really snaps into focus when you look at how they’re paid for and how success is judged. Detection companies like Eko Health, iRhythm, and AliveCor get funded based on their ability to get FDA clearances and prove their models can accurately find existing diseases. For them, success is measured by metrics like diagnostic accuracy, sensitivity, specificity, and how fast they can deliver a result.

Prevention programs are a different story. They’re usually paid for by employer health benefits or through partnerships with health plans. Success isn’t about a single diagnostic moment but about long-term results: lower blood pressure across a population, better medication adherence, fewer cardiac events over years, and healthier cardiovascular metrics overall. The ROI for prevention shows up as lower healthcare costs down the line, a more productive workforce, and better employee well-being. This requires a long-term view of value, which is very different from the immediate utility of a detection platform. This is why strategic work with bodies like the ACC and publishing peer-reviewed outcomes, like Hello Heart has done, become the gold standard for proving that a prevention program actually works and is worth the investment.